Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Artiva Biotherapeutics, Inc.

Get SEC filing alerts via email and in your feed for Artiva Biotherapeutics, Inc.

ARTV

Artiva Biotherapeutics, Inc.

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics develops off-the-shelf natural killer (NK) cell therapies targeting autoimmune diseases and cancers. Its lead candidate, AlloNK, enhances antibody-dependent cellular cytotoxicity (ADCC) in combination with B-cell targeted monoclonal antibodies, aiming to deplete pathogenic B-cells. The company focuses on scalable manufacturing, outpatient administration, and broad indications, leveraging proprietary processes and strategic collaborations to deliver accessible, safe, and effective cell therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Artiva Biotherapeutics, Inc.

1
1
Artiva Biotherapeutics, Inc. Artiva Biotherapeutics Reports $23.5 Million Net Loss in Q1 2026, Advances AlloNK Clinical Trials

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
Artiva Biotherapeutics, Inc. Artiva Biotherapeutics Reports $83.9 Million Net Loss and Progress on AlloNK in 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Artiva Biotherapeutics, Inc. Artiva Biotherapeutics Reports Q3 2025 Financial Results with Increased Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Artiva Biotherapeutics, Inc. Artiva Biotherapeutics Reports $21.3 Million Net Loss in Q2 2025, Increases R&D Spending

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Artiva Biotherapeutics, Inc. Artiva Biotherapeutics Reports $20.3 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Artiva Biotherapeutics, Inc. Artiva Biotherapeutics Reports $65.37 Million Net Loss for 2024, IPO Proceeds Boost Cash Reserves

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Artiva Biotherapeutics, Inc. Artiva Biotherapeutics Reports Significant Financial Developments, Including Increased Assets and Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments

8
1
Artiva Biotherapeutics, Inc. Artiva Biotherapeutics Reports Revenue Decline and Net Loss in Q2 2024

Via official filing (AI summary) | almost 2 years ago | 0 comments